HUTCHMED (China) Limited (HCM) Stock

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca.

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivot towards core operations at the drugmaker.

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —

SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

I am upgrading PYCR to a buy rating due to optimistic mid-term guidance and strong earnings growth potential. PYCR's new guidance indicates sustainable mid-teens recurring revenue growth and >800 bps adj EBIT margin expansion, driving >20% adj EBIT growth. Successful upmarket traction, increased sales headcount, and strong broker relationships are key drivers of PYCR's positive outlook.

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

SAN DIEGO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Paycor HCM, Inc. (NASDAQ: PYCR) to determine whether certain Paycor officers and directors violated securities laws and breached fiduciary duties to shareholders. Paycor HCM, together with its subsidiaries, engages in the provision of human capital management solutions for small and medium-sized businesses primarily in the United States.

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA ® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by its partner Takeda (TSE:4502/​NYSE:TAK).